Holen Sie sich die Stockscreener-App
15.39
1.77%
0.28
Mineralys Therapeutics Inc Aktie (MLYS) Neueste Nachrichten
Can a trend reversal in Mineralys Therapeutics Inc. lead to recoveryGap Down & Weekly Market Pulse Alerts - Newser
What recovery options are there for Mineralys Therapeutics Inc.July 2025 Outlook & Stock Portfolio Risk Management - Newser
Sentiment analysis tools applied to Mineralys Therapeutics Inc.2025 Top Decliners & Weekly Top Gainers Alerts - Newser
Using flow based indicators on Mineralys Therapeutics Inc.Dividend Hike & Safe Capital Growth Plans - Newser
How to recover losses in Mineralys Therapeutics Inc. stockJuly 2025 Opening Moves & Pattern Based Trade Signal System - Newser
Mineralys Therapeutics, Inc. (MLYS) Upgraded to Buy: Here's Why - MSN
Does Mineralys Therapeutics, Inc. (MLYS) Have the Potential to Rally 154.21% as Wall Street Analysts Expect? - MSN
Is Mineralys Therapeutics Inc. reversing from oversold territoryJuly 2025 Weekly Recap & Safe Swing Trade Setups - Newser
Is Mineralys Therapeutics Inc. forming a reversal patternTake Profit & Risk Adjusted Buy and Sell Alerts - Newser
Regression analysis insights on Mineralys Therapeutics Inc. performance2025 Top Decliners & Technical Entry and Exit Alerts - Newser
Mineralys Therapeutics Inc. stock momentum explainedJuly 2025 Sentiment & Safe Entry Point Alerts - Newser
Pattern recognition hints at Mineralys Therapeutics Inc. upsideEarnings Recap Summary & Growth Focused Stock Pick Reports - Newser
Analyzing recovery setups for Mineralys Therapeutics Inc. investorsM&A Rumor & AI Forecasted Stock Moves - Newser
Live market analysis of Mineralys Therapeutics Inc.Trade Volume Report & Weekly Stock Breakout Alerts - Newser
Can you recover from losses in Mineralys Therapeutics Inc.July 2025 PostEarnings & Free AI Powered Buy and Sell Recommendations - Newser
Will Mineralys Therapeutics Inc. stock split in the near futureTrade Entry Report & Accurate Technical Buy Alerts - Newser
Using portfolio simulators with Mineralys Therapeutics Inc. includedJuly 2025 Trends & Free Low Drawdown Momentum Trade Ideas - Newser
Will a bounce in Mineralys Therapeutics Inc. offer an exitJuly 2025 Review & Technical Analysis for Trade Confirmation - Newser
What to expect from Mineralys Therapeutics Inc. in the next 30 daysJuly 2025 Volume & Trade Opportunity Analysis - Newser
Mineralys Therapeutics Inc. stock prediction for this week2025 Major Catalysts & Breakout Confirmation Trade Signals - Newser
What Fibonacci levels say about Mineralys Therapeutics Inc. reboundStop Loss & Verified Stock Trade Ideas - Newser
Published on: 2025-08-24 19:47:19 - Newser
Does Mineralys Therapeutics Inc. stock benefit from AI growthEarnings Performance Report & Detailed Earnings Play Strategies - sundaytimes.kr
Should value investors consider Mineralys Therapeutics Inc.July 2025 Volume & AI Powered Buy and Sell Recommendations - theviewers.co.kr
How sensitive is Mineralys Therapeutics Inc. to inflationTrend Reversal & Safe Capital Preservation Plans - theviewers.co.kr
Is Mineralys Therapeutics Inc. likely to announce a buyback2025 Trading Volume Trends & Weekly Watchlist of Top Performers - theviewers.co.kr
Will Mineralys Therapeutics Inc. rebound enough to break evenJuly 2025 EndofMonth & Free Low Drawdown Momentum Trade Ideas - Newser
Is Mineralys Therapeutics Inc. currently under institutional pressure2025 Key Lessons & Precise Buy Zone Tips - theviewers.co.kr
Is Mineralys Therapeutics Inc.’s ROIC above industry averageDay Trade & Safe Entry Trade Reports - theviewers.co.kr
Is Mineralys Therapeutics Inc. undervalued by DCF analysisShare Buyback & Long-Term Safe Investment Plans - theviewers.co.kr
Is Mineralys Therapeutics Inc. affected by consumer sentiment2025 Earnings Surprises & Low Risk Entry Point Tips - theviewers.co.kr
Mineralys Therapeutics Inc. Builds Base for Possible ReboundJuly 2025 Big Picture & Verified Chart Pattern Trade Signals - beatles.ru
Mineralys Therapeutics Inc. Added to High Probability Setup ListJuly 2025 Macro Moves & Expert Curated Trade Setups - beatles.ru
Mineralys Therapeutics Reports Positive Topline Data from Phase 2 Explore-CKD Trial of Lorundrostat - MSN
Wall Street Analysts Believe Mineralys Therapeutics, Inc. (MLYS) Could Rally 149.66%: Here's is How to Trade - MSN
How to escape a deep drawdown in Mineralys Therapeutics Inc.July 2025 Sector Moves & Daily Entry Point Trade Alerts - Newser
Using data tools to time your Mineralys Therapeutics Inc. exitLayoff News & Verified Short-Term Plans - Newser
Jefferies maintains Hold rating on Mineralys Therapeutics stock ahead of competitor data By Investing.com - Investing.com South Africa
Jefferies maintains Hold rating on Mineralys Therapeutics stock ahead of competitor data - Investing.com Australia
Sector Leaders Rotate Capital Into Mineralys Therapeutics Inc.Portfolio Performance Summary & Accurate Intraday Trade Tips - newsimpact.co.kr
Full technical analysis of Mineralys Therapeutics Inc. stock2025 Market Outlook & Low Drawdown Momentum Trade Ideas - Newser
Analyzing drawdowns of Mineralys Therapeutics Inc. with statistical toolsMarket Performance Recap & Reliable Price Breakout Alerts - Newser
Published on: 2025-08-18 03:13:37 - sundaytimes.kr
Mineralys Therapeutics Advances Hypertension Drug Toward FDA Filing After Strong Clinical Results - MSN
Published on: 2025-08-17 09:08:08 - metal.it
Mineralys Therapeutics Inc. stock volume spike explained2025 Top Gainers & Stepwise Trade Signal Implementation - Newser
Will Mineralys Therapeutics Inc. announce a stock splitVolume Spike & Accurate Buy Signal Notifications - mustnews.co.kr
What momentum shifts mean for Mineralys Therapeutics Inc.Buy Signal & High Accuracy Buy Signal Tips - Newser
Mineralys Therapeutics to Announce Pivotal Trial Results for Lorundrostat - MSN
Mineralys Therapeutics CMO buys 6,349 shares, sells 11,365 shares in two-day trading period. - AInvest
Mineralys Therapeutics Inc. Enters Reversal Setup in Weekly ChartsWeekly Trend Summary & Free Safe Capital Growth Stock Tips - thegnnews.com
Mineralys Therapeutics shares fall 2.18% intraday after Q2 GAAP loss narrows and insider sells shares. - AInvest
0.24%
8.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):